Cogstate Ltd.

Cogstate Ltd. is a neuroscience technology company focused on optimizing the measurement of cognition to enhance brain health assessments. Founded in 1999 and listed on the Australian Securities Exchange, Cogstate delivers scientifically validated cognitive testing solutions for healthcare, clinical trials, and research institutions. The company's mission is to support the development of new treatments and provide earlier insights into brain health across various applications, including Alzheimer's, Parkinson's, and multiple sclerosis. Cogstate operates globally, collaborating with biopharmaceutical companies and academic institutions. Product Breakdown: Cogstate offers digital cognitive assessment tools designed to provide rapid, sensitive, and reliable evaluations of brain function. The core product, the Cogstate Brief Battery, is used in healthcare settings and clinical trials to measure cognition across diverse conditions such as Alzheimer's, schizophrenia, and oncology. The system includes tests that are quick to administer (10-15 minutes), providing immediate results. Cogstate's assessments are automated and flexible, making them adaptable for in-clinic or remote use. Their data solutions also ensure endpoint quality in clinical trials, enabling accurate and efficient monitoring of cognitive health.